Chemotherapy in advanced non-small cell lung cancer - PubMed (original) (raw)
Clinical Trial
Chemotherapy in advanced non-small cell lung cancer
T A Splinter. Eur J Cancer. 1990.
Abstract
Chemotherapy in advanced non-small cell lung cancer (NSCLC) has been evaluated with response rate, survival and quality of life as criteria. The data were collected from 142 phase II and III trials. The three main conclusions are: (1) multivariate landmark analyses show that a response to chemotherapy has an independent significant value for prognosis, and all studies of chemotherapy vs. best supportive care show some survival benefit in favour of chemotherapy; (2) NSCLC patients are a heterogeneous group with a large variation of known and unknown prognostic factors, such as the treatment centre, for both response and survival; and (3) retrospective analysis of the data show that response rate and survival are significantly correlated at response rate over 30% and in limited disease patients. The following recommendations are made: (1) new drugs should be compared in randomised phase II trials with a standard active drug; (2) randomised phase III trials of single agents or best supportive care vs. combination chemotherapy should be repeated in a well-defined subgroup of patients with a high performance score and limited tumour load; and (3) the palliative effect of chemotherapy in randomised trials in patients with symptoms should be investigated with relief of symptoms and quality of life as endpoints.
Similar articles
- [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
Kong Q, Wang XY, Jiang RC, Ba Y, Li K. Kong Q, et al. Zhonghua Zhong Liu Za Zhi. 2016 Apr;38(4):294-9. doi: 10.3760/cma.j.issn.0253-3766.2016.04.010. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 27087377 Chinese. - Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Hockenhull J, Proudlove C, Dundar Y, Richardson M, Dickson R, Mullard A, Marshall E. Greenhalgh J, et al. Health Technol Assess. 2015 Jun;19(47):1-134. doi: 10.3310/hta19470. Health Technol Assess. 2015. PMID: 26134145 Free PMC article. Review. - [Recent progress in chemotherapy for advanced lung cancer].
Negoro S, Fukuoka M. Negoro S, et al. Gan To Kagaku Ryoho. 1995 Mar;22(4):451-60. Gan To Kagaku Ryoho. 1995. PMID: 7887637 Review. Japanese. - Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Paz-Ares L, et al. Lancet Oncol. 2012 Mar;13(3):247-55. doi: 10.1016/S1470-2045(12)70063-3. Epub 2012 Feb 16. Lancet Oncol. 2012. PMID: 22341744 Clinical Trial.
Cited by
- Platinum drugs in the treatment of non-small-cell lung cancer.
Cosaert J, Quoix E. Cosaert J, et al. Br J Cancer. 2002 Oct 7;87(8):825-33. doi: 10.1038/sj.bjc.6600540. Br J Cancer. 2002. PMID: 12373594 Free PMC article. Review. - Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial.
Moinpour CM, Lyons B, Grevstad PK, Lovato LC, Crowley J, Czaplicki K, Buckner ZM, Ganz PA, Kelly K, Gandara DR. Moinpour CM, et al. Qual Life Res. 2002 Mar;11(2):115-26. doi: 10.1023/a:1015048908822. Qual Life Res. 2002. PMID: 12018735 Clinical Trial. - Phase II study of 4'-iodo-4'-deoxydoxorubicin in non-resectable non-small-cell lung cancer.
Sørensen JB, Stenbygaard L, Drivsholm L, Dombernowsky P, Hansen HH. Sørensen JB, et al. Cancer Chemother Pharmacol. 1993;32(5):399-402. doi: 10.1007/BF00735927. Cancer Chemother Pharmacol. 1993. PMID: 8393388 Clinical Trial. - Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study.
Millward MJ, Cantwell BM, Munro NC, Robinson A, Corris PA, Harris AL. Millward MJ, et al. Br J Cancer. 1993 May;67(5):1031-5. doi: 10.1038/bjc.1993.189. Br J Cancer. 1993. PMID: 8388231 Free PMC article. Clinical Trial. - Women with lung cancer: impact on quality of life.
Sarna L. Sarna L. Qual Life Res. 1993 Feb;2(1):13-22. doi: 10.1007/BF00642885. Qual Life Res. 1993. PMID: 8387854
Publication types
MeSH terms
LinkOut - more resources
Medical